Immunization of primates with a Newcastle disease virus-vectored vaccine via the respiratory tract induces a high titer of serum neutralizing antibodies against highly pathogenic avian influenza virus.
about
Newcastle Disease Virus as a Vaccine Vector for Development of Human and Veterinary VaccinesImmunogenicity and protective efficacy of a live attenuated H5N1 vaccine in nonhuman primatesAvian influenza pandemic preparedness: developing prepandemic and pandemic vaccines against a moving targetThe use of nonhuman primates in research on seasonal, pandemic and avian influenza, 1893-2014.Egg-independent vaccine strategies for highly pathogenic H5N1 influenza viruses.Newcastle disease virus-vectored vaccines expressing the hemagglutinin or neuraminidase protein of H5N1 highly pathogenic avian influenza virus protect against virus challenge in monkeys.Animal models for the preclinical evaluation of candidate influenza vaccines.A candidate H1N1 pandemic influenza vaccine elicits protective immunity in mice.Viral vector-based influenza vaccines.Targets for the induction of protective immunity against influenza a viruses.Protective efficacy of Newcastle disease virus expressing soluble trimeric hemagglutinin against highly pathogenic H5N1 influenza in chickens and mice.Experimental vaccines against potentially pandemic and highly pathogenic avian influenza virusesImmunization of chickens with Newcastle disease virus expressing H5 hemagglutinin protects against highly pathogenic H5N1 avian influenza viruses.Contributions of the avian influenza virus HA, NA, and M2 surface proteins to the induction of neutralizing antibodies and protective immunityInduction of influenza-specific mucosal immunity by an attenuated recombinant Sendai virus.Newcastle disease virus vector producing human norovirus-like particles induces serum, cellular, and mucosal immune responses in miceVirus-vectored influenza virus vaccines.Induction of type I interferon secretion through recombinant Newcastle disease virus expressing measles virus hemagglutinin stimulates antibody secretion in the presence of maternal antibodiesNewcastle disease virus expressing a dendritic cell-targeted HIV gag protein induces a potent gag-specific immune response in mice.Evaluation of the replication, pathogenicity, and immunogenicity of avian paramyxovirus (APMV) serotypes 2, 3, 4, 5, 7, and 9 in rhesus macaquesA host-restricted viral vector for antigen-specific immunization against Lyme disease pathogen.Newcastle disease virus-vectored rabies vaccine is safe, highly immunogenic, and provides long-lasting protection in dogs and catsNewcastle Disease Virus-Vectored H7 and H5 Live Vaccines Protect Chickens from Challenge with H7N9 or H5N1 Avian Influenza Viruses.Mucosal Immunization with Newcastle Disease Virus Vector Coexpressing HIV-1 Env and Gag Proteins Elicits Potent Serum, Mucosal, and Cellular Immune Responses That Protect against Vaccinia Virus Env and Gag Challenges.Aerosolized Ebola vaccine protects primates and elicits lung-resident T cell responsesImmunization of cattle with recombinant Newcastle disease virus expressing bovine herpesvirus-1 (BHV-1) glycoprotein D induces mucosal and serum antibody responses and provides partial protection against BHV-1.Respiratory tract immunization of non-human primates with a Newcastle disease virus-vectored vaccine candidate against Ebola virus elicits a neutralizing antibody responseEnhanced Immune Responses to HIV-1 Envelope Elicited by a Vaccine Regimen Consisting of Priming with Newcastle Disease Virus Expressing HIV gp160 and Boosting with gp120 and SOSIP gp140 ProteinsModified Newcastle disease virus vectors expressing the H5 hemagglutinin induce enhanced protection against highly pathogenic H5N1 avian influenza virus in chickensOptimization of human immunodeficiency virus gag expression by newcastle disease virus vectors for the induction of potent immune responses.Macaque models of human infectious disease.Delivery to the lower respiratory tract is required for effective immunization with Newcastle disease virus-vectored vaccines intended for humansPackaging and Prefusion Stabilization Separately and Additively Increase the Quantity and Quality of Respiratory Syncytial Virus (RSV)-Neutralizing Antibodies Induced by an RSV Fusion Protein Expressed by a Parainfluenza Virus Vector.RNA-based viral vectors.Recombinant Newcastle disease virus-vectored vaccines against human and animal infectious diseases.Intravenously injected Newcastle disease virus in non-human primates is safe to use for oncolytic virotherapy.Glycoprotein interactions in paramyxovirus fusion.Newcastle disease virus vectored vaccines as bivalent or antigen delivery vaccines.Distribution patterns of mucosally applied particles and characterization of the antigen presenting cells.A majority of infectious Newcastle disease virus particles contain a single genome, while a minority contain multiple genomes
P2860
Q26744220-F1446AE5-E6CF-4C14-80C5-BB252A78FB05Q28475369-F6B65376-E94B-469E-A866-D9F60CD44A7DQ30227194-6C5375AD-5933-474B-B37F-610B6958E641Q30372479-A748072C-1915-4321-8A36-E5EE8E5F9640Q30382097-E26FB887-63F6-49A7-A36B-A70C822E417AQ30382650-6709807B-D9BF-49E7-ACFF-6C09881A015EQ30383623-226771ED-7796-486E-89F5-94E8EB9BF2ACQ30389068-4998DC05-2DA9-4BEA-8E89-7B691544A799Q30390938-DC951BC8-79E8-4052-9756-78EAD3F87A73Q30408100-78F62AD2-8112-4B4F-92C6-7260F644B242Q30421007-9E82C1B3-7C3E-42D7-8E23-D329BD0C9A20Q30427591-FCDBA12F-5FDD-421F-98EA-6484771545D2Q33490614-0864F566-AE40-4533-ABBA-0061712EC58CQ33648987-A275035F-42AF-47EB-95BD-9964D659C525Q33886452-F94229A9-6A2B-4FDC-AE73-34C17438BDA2Q34059360-541DE9E8-53F7-4543-9837-9C8FE2894298Q34102268-522B3BDA-E3A7-45F4-8A85-26BE336ACB2AQ34457996-B10895E9-3E6D-499C-9EAC-AFFAE79B5A1BQ34741882-43CBC5F7-68C7-4BFE-B165-1248611C5B03Q35018292-F5748FA1-0677-4FD9-A91C-FC11444AD3B2Q35112976-E66F5F09-5DAC-4D32-BF0A-18A4F18C6AC1Q35140435-9F038293-9131-4C0F-BED6-E6408DF29F6CQ35618503-CBB8B0D3-1DA1-449F-8454-6DDA5BFBE62AQ35883750-7904BA1D-1704-4485-AAB7-C69C349762A6Q36040533-66565DA2-3F33-45A9-9163-78DE5D2A0DA6Q36190495-725E226A-217D-42D1-8A28-77EE5FEA964DQ36190519-3D594145-B46F-4E4E-9060-9C88742C4D58Q36481537-579DB7BA-06F3-4E3B-A127-EF54156C5780Q36692742-ECD14E68-2DA2-40D1-8E52-69B64647DE38Q37033299-C0E0672B-956B-447E-892A-2399EA1512C9Q37103536-8EEB02B3-529F-40A2-84D8-DBF2CE9E8D2FQ37297096-6A41699C-0553-4E01-9C1F-AB20A32F6B73Q37347267-D6D8BE13-48B0-40C2-B1DE-F9BB5C669F07Q38266413-7D44EEDD-EFD0-46D9-A1D5-36224A434A1EQ38559266-16908133-A751-4FD4-AD60-F189D010BCD7Q38953230-EE19A42C-3BFB-4D72-91A8-9E7B4474005BQ39900113-C527CE87-C528-4774-BD40-EA1615A65857Q40095159-84373C8D-6B92-4E55-A186-6B26DB4106A9Q41446178-E7267CA2-8B9B-4135-AEF3-0D3154DA2DC4Q41769686-E264D3C4-7AF5-4D08-BBB9-061D4B0E9602
P2860
Immunization of primates with a Newcastle disease virus-vectored vaccine via the respiratory tract induces a high titer of serum neutralizing antibodies against highly pathogenic avian influenza virus.
description
2007 nî lūn-bûn
@nan
2007 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
name
Immunization of primates with ...... hogenic avian influenza virus.
@ast
Immunization of primates with ...... hogenic avian influenza virus.
@en
type
label
Immunization of primates with ...... hogenic avian influenza virus.
@ast
Immunization of primates with ...... hogenic avian influenza virus.
@en
prefLabel
Immunization of primates with ...... hogenic avian influenza virus.
@ast
Immunization of primates with ...... hogenic avian influenza virus.
@en
P2093
P2860
P921
P356
P1433
P1476
Immunization of primates with ...... hogenic avian influenza virus.
@en
P2093
Alexander Bukreyev
Amorsolo Suguitan
Brian R Murphy
David W Dorward
Joshua M DiNapoli
Lijuan Yang
Peter L Collins
Siba K Samal
Subbiah Elankumaran
P2860
P304
11560-11568
P356
10.1128/JVI.00713-07
P577
2007-08-22T00:00:00Z